| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 257 |
| 1 | NIVOLUMAB | 102 |
| 2 | CARBOPLATIN | 73 |
| 3 | IPILIMUMAB | 57 |
| 4 | PACLITAXEL | 46 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 39 |
| 6 | CISPLATIN | 37 |
| 7 | PEMETREXED DISODIUM | 35 |
| 8 | FLUOROURACIL | 25 |
| 9 | FLUOROURACIL CREAM, 0.5% | 25 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PEMBROLIZUMAB | 257 | 0.0024 |
| 1 | PLATINUM | 1 | 0.0019 |
| 2 | TREMELIMUMAB | 8 | 0.0018 |
| 3 | NALDEMEDINE | 3 | 0.0018 |
| 4 | CEMIPLIMAB-RWLC | 3 | 0.0014 |
| 5 | IPILIMUMAB | 57 | 0.0013 |
| 6 | ENFORTUMAB VEDOTIN | 10 | 0.0013 |
| 7 | SENNOSIDES A AND B | 2 | 0.0012 |
| 8 | PEMIGATINIB | 1 | 0.0012 |
| 9 | LEVOLEUCOVORIN | 4 | 0.0010 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 65 | 0.0013 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 102 | 0.0010 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 19 | 0.0009 |
| 3 | Platinum-based Drug [EPC] | 122 | 0.0004 |
| 4 | Cytomegalovirus pUL97 Kinase Inhibitor [EPC] | 1 | 0.0004 |
| 5 | Microtubule Inhibitor [EPC] | 47 | 0.0003 |
| 6 | Chloride Channel Activator [EPC] | 2 | 0.0002 |
| 7 | alpha-Glucosidase Inhibitor [EPC] | 1 | 0.0002 |
| 8 | CD30-directed Immunoconjugate [EPC] | 2 | 0.0002 |
| 9 | Osmotic Diuretic [EPC] | 1 | 0.0002 |